menu
    • menu

    Company profile for Imbrium Therapeutics

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Imbrium Therapeutics is a clinical stage biopharmaceutical company dedicated to advancing medical science through the development of important new therapies to treat cancer, pain and disorders of the central nervous system. Imbrium Therapeutics was founded in 2019 as an operating subsidiary of Purdue Pharma. With its distinct mission, therapy area focus, and leadership team, Imbrium is committed to applying its capabilities in...
    Imbrium Therapeutics is a clinical stage biopharmaceutical company dedicated to advancing medical science through the development of important new therapies to treat cancer, pain and disorders of the central nervous system. Imbrium Therapeutics was founded in 2019 as an operating subsidiary of Purdue Pharma. With its distinct mission, therapy area focus, and leadership team, Imbrium is committed to applying its capabilities in science and medicine to rapidly advance the development of new, favorably differentiated therapeutic agents in the areas of cancer, CNS and non-opioid pain.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Imbrium TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    201 Tresser Boulevard, Stamford, CT 06901-3431
    Telephone
    Telephone
    888-827-0622
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.imbriumthera.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/imbrium-therapeutics
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/ImbriumThera

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Imbrium Therapeutics to Showcase Pipeline Assets at BIO 2025
    Imbrium Therapeutics to Showcase Pipeline Assets at BIO 2025

    16 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250616442591/en/Imbrium-Therapeutics-to-Showcase-Pipeline-Assets-Open-for-Partnership-at-the-BIO-International-Convention-2025

    BUSINESSWIRE
    16 Jun 2025
    Share Share
    Imbrium Therapeutics Achieves Last Patient Last Visit in Clinical Trial
    Imbrium Therapeutics Achieves Last Patient Last Visit in Clinical Trial

    11 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250311007864/en

    BUSINESSWIRE
    11 Mar 2025
    Share Share
    Imbrium Phase 1b Data For Sunobinop In Overactive Bladder Syndrome
    Imbrium Phase 1b Data For Sunobinop In Overactive Bladder Syndrome

    07 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250107207362/en

    BUSINESSWIRE
    07 Jan 2025
    Share Share
    Imbrium Therapeutics Files IND For Sunobinop In Alcohol Use Disorder
    Imbrium Therapeutics Files IND For Sunobinop In Alcohol Use Disorder

    05 Aug 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240805846833/en

    BUSINESSWIRE
    05 Aug 2024
    Share Share
    Imbrium Completes Clinical Trial For Overactive Bladder Treatment
    Imbrium Completes Clinical Trial For Overactive Bladder Treatment

    09 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240709392458/en

    BUSINESSWIRE
    09 Jul 2024
    Share Share
    Imbrium Completes First Patient Visit in Ph1 Study of Potential Treatment
    Imbrium Completes First Patient Visit in Ph1 Study of Potential Treatment

    20 Dec 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221219005799/en

    BUSINESSWIRE
    20 Dec 2022
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search